{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:18:36Z","timestamp":1789759116838,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14477-2","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:53:30Z","timestamp":1758740010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells"],"prefix":"10.1186","volume":"25","author":[{"given":"Amirhesan","family":"Yahyapour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-1144","authenticated-orcid":false,"given":"Nahid","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Yaghoobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"2","key":"14477_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers16020461","volume":"16","author":"B Victoir","year":"2024","unstructured":"Victoir B, Croix C, Gouilleux F, Pri\u00e9 G. Targeted therapeutic strategies for the treatment of Cancer. Cancers. 2024;16(2):461.","journal-title":"Cancers"},{"key":"14477_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.20517\/2394-4722.2022.08","volume":"8","author":"P Vafopoulou","year":"2022","unstructured":"Vafopoulou P, Kourti M. Anti-angiogenic drugs in cancer therapeutics: A review of the latest preclinical and clinical studies of anti-angiogenic agents with anticancer potential. J Cancer Metastasis Treat. 2022;8:18.","journal-title":"J Cancer Metastasis Treat"},{"issue":"1","key":"14477_CR3","doi-asserted-by":"publisher","first-page":"11853","DOI":"10.1038\/srep11853","volume":"5","author":"N Mohammad","year":"2015","unstructured":"Mohammad N, Vikram Singh S, Malvi P, Chaube B, Athavale D, Vanuopadath M, et al. Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-\u03b2-cyclodextrin: involvement of p53 and Fas receptor ligand complex. Sci Rep. 2015;5(1):11853.","journal-title":"Sci Rep"},{"key":"14477_CR4","doi-asserted-by":"crossref","unstructured":"Rom\u00e3o IC, Siqueira SMC, Silva Abreu, FOMd. Santos hsd. Hydralazine and hydrazine derivatives: properties, applications, and repositioning potential. Chemistry & Biodiversity; 2024. n\/a(n\/a):e202401561.","DOI":"10.1002\/cbdv.202401561"},{"issue":"3","key":"14477_CR5","first-page":"938","volume":"12","author":"Y Jin","year":"2022","unstructured":"Jin Y, Teh SS, Lau HLN, Xiao J, Mah SH. Retinoids as anti-cancer agents and their mechanisms of action. Am J Cancer Res. 2022;12(3):938.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"14477_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"D1","key":"14477_CR7","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, et al. DrugBank 6.0: the drugbank knowledgebase for 2024. Nucleic Acids Res. 2024;52(D1):D1265\u201375.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"14477_CR8","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357\u201364.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"14477_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s10593-014-1496-1","volume":"50","author":"DA Filimonov","year":"2014","unstructured":"Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV, et al. Prediction of the biological activity spectra of organic compounds using the pass online web resource. Chem Heterocycl Compd. 2014;50(3):444\u201357.","journal-title":"Chem Heterocycl Compd"},{"issue":"5","key":"14477_CR10","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/ijms22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B. TNMplot.com: A web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22(5):2622.","journal-title":"Int J Mol Sci"},{"key":"14477_CR11","doi-asserted-by":"crossref","unstructured":"Gy\u0151rffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innov. 2024;5(3).","DOI":"10.1016\/j.xinn.2024.100625"},{"issue":"8","key":"14477_CR12","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","volume":"36","author":"SX Ge","year":"2019","unstructured":"Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2019;36(8):2628\u20139.","journal-title":"Bioinformatics"},{"issue":"2","key":"14477_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/ph17020195","volume":"17","author":"RA Qannita","year":"2024","unstructured":"Qannita RA, Alalami AI, Harb AA, Aleidi SM, Taneera J, Abu-Gharbieh E, et al. Targeting hypoxia-inducible Factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation. Pharmaceuticals. 2024;17(2):195.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"14477_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez M, Malumbres M. Mechanisms of sensitivity and resistance to CDK4\/6 Inhibition. Cancer Cell. 2020;37(4):514\u201329.","journal-title":"Cancer Cell"},{"issue":"3","key":"14477_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5114\/wo.2023.133742","volume":"27","author":"M Hamad","year":"2023","unstructured":"Hamad M, Mehana RA, Abd-Al haseeb MM, Houssen M. Potential antitumour effect of all-trans retinoic acid on regorafenib-treated human colon cancer cell lines. Contemp Oncology\/Wsp\u00f3\u0142czesna Onkologia. 2023;27(3):198\u2013210.","journal-title":"Contemp Oncology\/Wsp\u00f3\u0142czesna Onkologia"},{"key":"14477_CR16","doi-asserted-by":"crossref","unstructured":"Xi H-M, Lu H, Weng X-Q, Sheng Y, Wu J, Li L et al. Combined application of salinomycin and ATRA induces apoptosis and differentiation of acute myeloid leukemia cells by inhibiting WNT\/\u03b2-Catenin pathway. Anti-Cancer agents in medicinal chemistry (Formerly current medicinal chemistry-Anti-Cancer agents). 2023;23(9):1074\u201384.","DOI":"10.2174\/1871520623666230110121629"},{"issue":"1","key":"14477_CR17","doi-asserted-by":"publisher","first-page":"A23","DOI":"10.1186\/1471-2407-7-S1-A23","volume":"7","author":"C Arce","year":"2007","unstructured":"Arce C, Perez-Plasencia C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A, et al. A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer. BMC Cancer. 2007;7(1):A23.","journal-title":"BMC Cancer"},{"issue":"1","key":"14477_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s12032-010-9700-3","volume":"28","author":"J Coronel","year":"2011","unstructured":"Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonz\u00e1lez-Fierro A, de la Cruz-Hernandez E, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol. 2011;28(1):540\u20136.","journal-title":"Med Oncol"},{"issue":"1","key":"14477_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2407-5-44","volume":"5","author":"P Zambrano","year":"2005","unstructured":"Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L, et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer. 2005;5(1):44.","journal-title":"BMC Cancer"},{"issue":"23","key":"14477_CR20","first-page":"8492","volume":"61","author":"PN Munster","year":"2001","unstructured":"Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001;61(23):8492\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"14477_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"21","key":"14477_CR22","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1200\/JCO.2009.26.6452","volume":"28","author":"O Arrieta","year":"2010","unstructured":"Arrieta O, Gonz\u00e1lez-De la Rosa CH, Ar\u00e9chaga-Ocampo E, Villanueva-Rodr\u00edguez G, Cer\u00f3n-Liz\u00e1rraga TL, Mart\u00ednez-Barrera L, et al. Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on Paclitaxel and cisplatin as first-line treatment in patients with advanced non\u2013small-cell lung cancer. J Clin Oncol. 2010;28(21):3463\u201371.","journal-title":"J Clin Oncol"},{"key":"14477_CR23","doi-asserted-by":"crossref","unstructured":"Petersen OW, R\u00f8nnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proceedings of the National Academy of Sciences. 1992;89(19):9064-8.","DOI":"10.1073\/pnas.89.19.9064"},{"issue":"3","key":"14477_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1139\/bcb-2019-0117","volume":"98","author":"M Mehrabani","year":"2020","unstructured":"Mehrabani M, Nematollahi MH, Tarzi ME, Juybari KB, Abolhassani M, Sharifi AM, et al. Protective effect of hydralazine on a cellular model of parkinson\u2019s disease: a possible role of hypoxia-inducible factor (HIF)-1\u03b1. Biochem Cell Biol. 2020;98(3):405\u201314.","journal-title":"Biochem Cell Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14477-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14477-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14477-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:53:32Z","timestamp":1758740012000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14477-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14477"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14477-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval (Code: 02.83760; Date: 12 January 2024) was granted by the Ethics Committee of KGUT\u2019s Institute of Sciences and High Technology and Environmental Sciences, confirming adherence to institutional ethical standards for research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1427"}}